SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
XNCR
--
0.00%
--
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 05/29 11:22
Edited Transcript of XNCR earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Xencor Inc Earnings Call
Thomson Reuters StreetEvents · 05/28 18:52
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will par
Business Wire · 05/26 20:01
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Benzinga · 05/24 18:40
Xencor to Present Data from Four Preclinical XmAb 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR) announced it will present new preclinical data on three XmAb® 2+1 bispecific antibody programs and an IL-12-Fc cytokine program at the second session of the American Association for Cancer Research (AACR) Virtual Annual Meeting, bei
Benzinga · 05/15 09:27
Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb® 2+1 bispecific antibody
Business Wire · 05/15 04:01
Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb In Solid Tumors: 'generally well-tolerated and a confirmed complete response observed at highest dose level tested'
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the
Benzinga · 05/13 21:10
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®20717, a
Business Wire · 05/13 21:00
Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will par
Business Wire · 05/13 13:01
Growth Investors: Industry Analysts Just Upgraded Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts By 22%
Simply Wall St. · 05/11 18:35
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 09:14
Xencor Inc (XNCR) Q1 2020 Earnings Call Transcript
Today on our call, Bassil Dahiyat, President and Chief Executive Officer; will provide updates regarding COVID-19, our portfolio programs and licensing partnerships; John Kuch, Senior Vice President and Chief Financial Officer, will review the financial result
Motley Fool · 05/09 01:30
Xencor EPS beats by $0.25, beats on revenue
Xencor (NASDAQ:XNCR): Q1 GAAP EPS of -$0.14 beats by $0.25. Revenue of $32.4M (-71.1% Y/Y) beats by $17.74M. Press Release
seekingalpha · 05/08 01:11
Xencor Q1 EPS $(0.140) Beats $(0.380) Estimate, Sales $32.385M Beat $15.060M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.140) per share which beat the analyst consensus estimate of $(0.380) by 63.16 percent. This is a 110.14 percent decrease over earnings of $1.380 per share from the
Benzinga · 05/07 20:09
Xencor Reports First Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2020 and provided a r
Business Wire · 05/07 20:01
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after the market c
Business Wire · 04/30 20:01
RemeGen candidate Fast Track'd for lupus
Seeking Alpha - Article · 04/15 15:13
Introducing Xencor (NASDAQ:XNCR), The Stock That Zoomed 109% In The Last Five Years
Simply Wall St. · 04/13 20:49
Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology
MotleyFool.com · 04/12 12:31
Hedge Funds Are Buying Xencor Inc (XNCR)
Insider Monkey · 04/07 19:10